Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo, California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19 found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company record rather than an API listing.
Labrys Biologics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.
aid: labrys-biologics
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-11-06'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/labrys-biologics.png
name: Labrys Biologics
description: 'Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo,
California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention
of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired
by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys
Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19
found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva
nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company
record rather than an API listing.'
url: https://raw.githubusercontent.com/api-evangelist/labrys-biologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: teva
x-acquired-year: 2014
x-operating: false
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Neurology
- Clinical Research
- Acquired
apis: []
common:
- type: DomainSecurity
url: security/labrys-biologics-domain-security.yml
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.